Discovery research and development history of the dopamine D 2 receptor partial agonists, aripiprazole and brexpiprazole

Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D 2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify ® ). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europ...

Full description

Saved in:
Bibliographic Details
Published inNeuropsychopharmacology reports Vol. 41; no. 2; pp. 134 - 143
Main Authors Kikuchi, Tetsuro, Maeda, Kenji, Suzuki, Mikio, Hirose, Tsuyoshi, Futamura, Takashi, McQuade, Robert D.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.06.2021
Subjects
Agonists
Antipsychotics
Aripiprazole - therapeutic use
Depressive Disorder, Major - drug therapy
Dopamine
Dopamine Agonists - therapeutic use
Drug dosages
Humans
Hypotheses
Psychotropic drugs
Quinolones
R&D
Research & development
Schizophrenia
Serotonin
Thiophenes
United States
United States
Canada
United States > US
Japan
Europe
aripiprazole
dopamine-system stabilizer
brexpiprazole
dopamine D2 receptor partial agonist
serotonin-dopamine activity modulator
Online AccessGet full text

Cover

Abstract Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D 2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify ® ). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europe, Japan, and many other countries for several indications including schizophrenia, acute mania, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette's disorder. Otsuka next developed brexpiprazole (Rexulti ® ), another D 2 receptor partial agonist, which was granted marketing approval in the United States in 2015 as adjunctive therapy in major depressive disorder and for the treatment of schizophrenia. In Japan, brexpiprazole also received approval as a treatment for schizophrenia in 2018. In this review, we describe Otsuka's research history and achievements over the preceding 40 years in the area of antipsychotic drug discovery for dopamine D 2 receptor partial agonists.
AbstractList Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify ). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europe, Japan, and many other countries for several indications including schizophrenia, acute mania, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette's disorder. Otsuka next developed brexpiprazole (Rexulti ), another D receptor partial agonist, which was granted marketing approval in the United States in 2015 as adjunctive therapy in major depressive disorder and for the treatment of schizophrenia. In Japan, brexpiprazole also received approval as a treatment for schizophrenia in 2018. In this review, we describe Otsuka's research history and achievements over the preceding 40 years in the area of antipsychotic drug discovery for dopamine D receptor partial agonists.
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify®). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europe, Japan, and many other countries for several indications including schizophrenia, acute mania, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette's disorder. Otsuka next developed brexpiprazole (Rexulti®), another D2 receptor partial agonist, which was granted marketing approval in the United States in 2015 as adjunctive therapy in major depressive disorder and for the treatment of schizophrenia. In Japan, brexpiprazole also received approval as a treatment for schizophrenia in 2018. In this review, we describe Otsuka's research history and achievements over the preceding 40 years in the area of antipsychotic drug discovery for dopamine D2 receptor partial agonists.
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D 2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify ® ). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europe, Japan, and many other countries for several indications including schizophrenia, acute mania, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder, and Tourette's disorder. Otsuka next developed brexpiprazole (Rexulti ® ), another D 2 receptor partial agonist, which was granted marketing approval in the United States in 2015 as adjunctive therapy in major depressive disorder and for the treatment of schizophrenia. In Japan, brexpiprazole also received approval as a treatment for schizophrenia in 2018. In this review, we describe Otsuka's research history and achievements over the preceding 40 years in the area of antipsychotic drug discovery for dopamine D 2 receptor partial agonists.
Author Maeda, Kenji
Kikuchi, Tetsuro
Suzuki, Mikio
Hirose, Tsuyoshi
McQuade, Robert D.
Futamura, Takashi
Author_xml – sequence: 1
  givenname: Tetsuro
  orcidid: 0000-0002-3902-7302
  surname: Kikuchi
  fullname: Kikuchi, Tetsuro
  organization: New Drug Research Division Pharmaceutical Business Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan
– sequence: 2
  givenname: Kenji
  surname: Maeda
  fullname: Maeda, Kenji
  organization: Department of Lead Discovery Research New Drug Research Division Pharmaceutical Business Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan
– sequence: 3
  givenname: Mikio
  surname: Suzuki
  fullname: Suzuki, Mikio
  organization: Department of CNS Research New Drug Research Division Pharmaceutical Business Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan
– sequence: 4
  givenname: Tsuyoshi
  surname: Hirose
  fullname: Hirose, Tsuyoshi
  organization: New Drug Research Division Pharmaceutical Business Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan
– sequence: 5
  givenname: Takashi
  surname: Futamura
  fullname: Futamura, Takashi
  organization: Department of CNS Research New Drug Research Division Pharmaceutical Business Division Otsuka Pharmaceutical Co., Ltd. Tokushima Japan
– sequence: 6
  givenname: Robert D.
  surname: McQuade
  fullname: McQuade, Robert D.
  organization: Otsuka Pharmaceutical Development & Commercialization, Inc. Princeton NJ USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33960741$$D View this record in MEDLINE/PubMed
BookMark eNpt0VtLBCEUB3CJovtLHyCE3qItdbQZH2O7QtBLQW_DWedMa8yqqRvVp8_tRkQPonh-5wj-N8iy8w4J2eHskDMmjlyI4pAL3rAlsi5ULUe8ru6Xf53XyHZKj6zgxarkKlmrKn3MasnXycupTcY_Y3ylERNCNFMKrqMdPuPgwwxdplObsi_A9zRPkXY-wMw6pKdUlCaDoVRpgJgtDBQevCs-HVCINtgQ4c0P-DFzEvHl52aLrPQwJNz-2jfJ3fnZ7fhydH1zcTU-uR4ZwUUedQ0zALqWnZDyuBdCNVpzjsC0FlqC7CdSSYQaCmjMhBvVNxVqVLpbVKpNsvc5N0T_NMeU20c_j6482QpVqbqWqlFF7X6p-WSGXRuinUF8bb8_qoD9T2CiTyli_0M4axdBtIsg2o8gCmZ_sLEZsvUuR7DDfy3vOhSMMg
CitedBy_id crossref_primary_10_1002_npr2_12317
crossref_primary_10_1007_s12325_025_03130_w
crossref_primary_10_1016_j_ejpb_2023_06_013
crossref_primary_10_1080_13651501_2022_2151473
crossref_primary_10_3389_fpsyt_2023_1257460
crossref_primary_10_1007_s43440_022_00440_6
crossref_primary_10_1016_j_neuropharm_2023_109546
crossref_primary_10_1002_ptr_8002
crossref_primary_10_1177_20451253231198463
crossref_primary_10_1002_14651858_CD014670
crossref_primary_10_7759_cureus_73269
crossref_primary_10_51847_bNMXd353X2
crossref_primary_10_1097_MJT_0000000000001425
crossref_primary_10_3390_medicina58111584
crossref_primary_10_3390_brainsci13030397
crossref_primary_10_12677_acm_2024_14123119
crossref_primary_10_14412_2074_2711_2024_4_4_13
crossref_primary_10_1007_s40263_024_01124_w
crossref_primary_10_3390_ijms231810624
crossref_primary_10_1002_psb_2147
crossref_primary_10_1016_j_lfs_2022_121366
crossref_primary_10_1016_j_bbrep_2023_101594
crossref_primary_10_1038_s41392_023_01427_2
crossref_primary_10_1111_pcn_13438
crossref_primary_10_1021_acs_jmedchem_3c00098
crossref_primary_10_1155_2022_8425640
Cites_doi 10.1017/S1461145709000327
10.1038/sj.npp.1300203
10.1093/sleep/14.2.130
10.1111/pcn.12654
10.1016/j.euroneuro.2014.12.014
10.1016/j.brainres.2003.09.082
10.3389/fpsyt.2017.00144
10.1017/S1461145713001417
10.1007/978-3-642-25761-2_4
10.1016/S0014-2999(03)01308-6
10.1124/jpet.114.213793
10.3371/CSRP.MCCI.010316
10.1177/1039856219889303
10.1097/JCP.0000000000000665
10.1111/pcn.12682
10.1016/j.bmcl.2005.05.104
10.1002/npr2.12076
10.1097/JCP.0000000000000979
10.1016/j.ejphar.2009.02.007
10.1016/S0893-133X(01)00263-9
10.1007/s00213-014-3459-8
10.1124/jpet.102.033175
10.1093/schbul/sbr006
10.1038/s41380-020-0852-z
10.1523/JNEUROSCI.22-07-02873.2002
10.1097/01.pra.0000452561.98286.1e
10.1097/YIC.0000000000000123
10.1001/archpsyc.60.7.681
10.1016/j.schres.2014.12.013
10.1016/j.ejphar.2005.02.051
10.1016/S0006-3223(00)01025-8
10.1592/phco.29.1.64
10.1016/S0924-977X(99)00053-X
10.1016/j.schres.2019.05.006
10.1016/j.euroneuro.2017.11.017
10.1111/bcpt.12090
10.1007/s00213-008-1240-6
10.1586/14737175.2015.1086269
10.2174/1568007024606221
10.1016/j.schres.2016.04.013
10.1517/13543776.2011.565333
10.1016/0024-3205(88)90493-6
10.1177/0269881117728428
10.1021/jm940608g
10.1016/j.pbb.2014.06.008
10.4088/JCP.v62n1201
10.4088/JCP.v63n0903
10.4088/JCP.11m07530
10.1097/JCP.0b013e31828ea95c
10.1124/jpet.114.213819
10.1016/S0920-9964(03)00050-1
ContentType Journal Article
Copyright 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsychopharmacology.
2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsychopharmacology.
– notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
DOI 10.1002/npr2.12180
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest - Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Psychology
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList MEDLINE
Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2574-173X
EndPage 143
ExternalDocumentID 33960741
10_1002_npr2_12180
Genre Journal Article
Review
GeographicLocations United States
Canada
United States--US
Japan
Europe
GeographicLocations_xml – name: United States
– name: Canada
– name: United States--US
– name: Europe
– name: Japan
GroupedDBID 0R~
1OC
24P
7X7
8FI
8FJ
AAHHS
AAYXX
ABDBF
ABUWG
ACCFJ
ACCMX
ACGFS
ACUHS
ACXQS
ADBBV
ADKYN
ADPDF
ADZMN
AEEZP
AEQDE
AFKRA
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AVUZU
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
EBS
EJD
FYUFA
GROUPED_DOAJ
HMCUK
IAO
IHR
INH
IPY
ITC
M~E
O9-
OK1
OVD
OVEED
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSYQQ
RPM
TEORI
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
WIN
3V.
7XB
8FK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
ID FETCH-LOGICAL-c212t-d80caa974d2446f22589911ea099294a4fb454ea7ad248cb1c5f83e9e59db4543
IEDL.DBID 7X7
ISSN 2574-173X
IngestDate Sat Aug 23 12:54:52 EDT 2025
Wed Feb 19 02:27:12 EST 2025
Thu Apr 24 23:08:54 EDT 2025
Tue Jul 01 03:07:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords aripiprazole
dopamine-system stabilizer
brexpiprazole
dopamine D2 receptor partial agonist
serotonin-dopamine activity modulator
Language English
License 2021 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Society of Neuropsychopharmacology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c212t-d80caa974d2446f22589911ea099294a4fb454ea7ad248cb1c5f83e9e59db4543
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ORCID 0000-0002-3902-7302
OpenAccessLink https://www.proquest.com/docview/2535774585?pq-origsite=%requestingapplication%
PMID 33960741
PQID 2535774585
PQPubID 4378887
PageCount 10
ParticipantIDs proquest_journals_2535774585
pubmed_primary_33960741
crossref_primary_10_1002_npr2_12180
crossref_citationtrail_10_1002_npr2_12180
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-06-00
20210601
PublicationDateYYYYMMDD 2021-06-01
PublicationDate_xml – month: 06
  year: 2021
  text: 2021-06-00
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Neuropsychopharmacology reports
PublicationTitleAlternate Neuropsychopharmacol Rep
PublicationYear 2021
Publisher John Wiley & Sons, Inc
Publisher_xml – name: John Wiley & Sons, Inc
References Kikuchi T (e_1_2_9_4_1) 1995; 274
e_1_2_9_31_1
e_1_2_9_52_1
e_1_2_9_50_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_56_1
Inanaga K (e_1_2_9_34_1) 1972; 26
e_1_2_9_12_1
e_1_2_9_33_1
e_1_2_9_54_1
Risch SC (e_1_2_9_17_1) 1996; 16
Newcomer JW (e_1_2_9_14_1) 2005; 19
Potkin SG (e_1_2_9_22_1) 2017; 20
e_1_2_9_39_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_58_1
e_1_2_9_18_1
e_1_2_9_41_1
e_1_2_9_20_1
e_1_2_9_45_1
e_1_2_9_24_1
e_1_2_9_43_1
e_1_2_9_8_1
e_1_2_9_6_1
e_1_2_9_60_1
e_1_2_9_2_1
e_1_2_9_26_1
e_1_2_9_49_1
e_1_2_9_28_1
Miyamoto S (e_1_2_9_36_1) 2000; 2
e_1_2_9_47_1
e_1_2_9_53_1
e_1_2_9_51_1
e_1_2_9_11_1
e_1_2_9_57_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_55_1
Inoue T (e_1_2_9_38_1) 1996; 277
e_1_2_9_59_1
e_1_2_9_19_1
Miller CH (e_1_2_9_30_1) 1990; 26
e_1_2_9_42_1
e_1_2_9_40_1
e_1_2_9_61_1
e_1_2_9_21_1
e_1_2_9_46_1
e_1_2_9_23_1
e_1_2_9_44_1
e_1_2_9_7_1
e_1_2_9_5_1
Carlsson A (e_1_2_9_15_1) 1972; 24
e_1_2_9_3_1
e_1_2_9_9_1
e_1_2_9_25_1
e_1_2_9_27_1
e_1_2_9_48_1
e_1_2_9_29_1
References_xml – ident: e_1_2_9_21_1
  doi: 10.1017/S1461145709000327
– volume: 274
  start-page: 329
  issue: 1
  year: 1995
  ident: e_1_2_9_4_1
  article-title: 7‐{4‐[4‐(2,3‐Dichlorophenyl)‐1‐piperazinyl]butyloxy}‐3,4‐dihydro‐2(1H)‐quinolinone (OPC‐14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity
  publication-title: J Pharmacol Exp Ther
– ident: e_1_2_9_27_1
  doi: 10.1038/sj.npp.1300203
– ident: e_1_2_9_28_1
  doi: 10.1093/sleep/14.2.130
– ident: e_1_2_9_46_1
  doi: 10.1111/pcn.12654
– ident: e_1_2_9_48_1
  doi: 10.1016/j.euroneuro.2014.12.014
– ident: e_1_2_9_39_1
  doi: 10.1016/j.brainres.2003.09.082
– ident: e_1_2_9_60_1
  doi: 10.3389/fpsyt.2017.00144
– volume: 20
  start-page: 40
  issue: 1
  year: 2017
  ident: e_1_2_9_22_1
  article-title: Multidimensional assessment of functional outcomes in schizophrenia: results from qualify, a head‐to‐head trial of aripiprazole once‐monthly and paliperidone palmitate
  publication-title: Int J Neuropsychopharmacol
– volume: 16
  start-page: 11
  issue: 1
  year: 1996
  ident: e_1_2_9_17_1
  article-title: Pathophysiology of schizophrenia and the role of newer antipsychotics
  publication-title: Pharmacotherapy
– ident: e_1_2_9_31_1
  doi: 10.1017/S1461145713001417
– ident: e_1_2_9_37_1
  doi: 10.1007/978-3-642-25761-2_4
– ident: e_1_2_9_61_1
  doi: 10.1016/S0014-2999(03)01308-6
– ident: e_1_2_9_11_1
  doi: 10.1124/jpet.114.213793
– ident: e_1_2_9_43_1
  doi: 10.3371/CSRP.MCCI.010316
– ident: e_1_2_9_56_1
  doi: 10.1177/1039856219889303
– ident: e_1_2_9_44_1
  doi: 10.1097/JCP.0000000000000665
– ident: e_1_2_9_45_1
  doi: 10.1111/pcn.12682
– volume: 19
  start-page: 1
  issue: 1
  year: 2005
  ident: e_1_2_9_14_1
  article-title: Second‐generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review
  publication-title: CNS Drugs
– ident: e_1_2_9_29_1
  doi: 10.1016/j.bmcl.2005.05.104
– ident: e_1_2_9_40_1
  doi: 10.1002/npr2.12076
– ident: e_1_2_9_47_1
  doi: 10.1097/JCP.0000000000000979
– ident: e_1_2_9_18_1
  doi: 10.1016/j.ejphar.2009.02.007
– volume: 2
  start-page: 25
  issue: 1
  year: 2000
  ident: e_1_2_9_36_1
  article-title: Developing novel antipsychotic drugs: strategies and goals
  publication-title: Curr Opin CPNS Invest Drugs
– ident: e_1_2_9_19_1
  doi: 10.1016/S0893-133X(01)00263-9
– ident: e_1_2_9_59_1
  doi: 10.1007/s00213-014-3459-8
– ident: e_1_2_9_2_1
  doi: 10.1124/jpet.102.033175
– ident: e_1_2_9_25_1
  doi: 10.1093/schbul/sbr006
– ident: e_1_2_9_55_1
  doi: 10.1038/s41380-020-0852-z
– volume: 26
  start-page: 145
  issue: 2
  year: 1972
  ident: e_1_2_9_34_1
  article-title: Effect of L‐DOPA in schizophrenia
  publication-title: Folia Psychiatr Neurol Jpn
– ident: e_1_2_9_52_1
  doi: 10.1523/JNEUROSCI.22-07-02873.2002
– ident: e_1_2_9_53_1
  doi: 10.1097/01.pra.0000452561.98286.1e
– ident: e_1_2_9_42_1
  doi: 10.1097/YIC.0000000000000123
– ident: e_1_2_9_8_1
  doi: 10.1001/archpsyc.60.7.681
– ident: e_1_2_9_10_1
  doi: 10.1016/j.schres.2014.12.013
– ident: e_1_2_9_3_1
  doi: 10.1016/j.ejphar.2005.02.051
– ident: e_1_2_9_33_1
  doi: 10.1016/S0006-3223(00)01025-8
– ident: e_1_2_9_20_1
  doi: 10.1592/phco.29.1.64
– ident: e_1_2_9_32_1
  doi: 10.1016/S0924-977X(99)00053-X
– ident: e_1_2_9_51_1
  doi: 10.1016/j.schres.2019.05.006
– ident: e_1_2_9_54_1
  doi: 10.1016/j.euroneuro.2017.11.017
– ident: e_1_2_9_58_1
  doi: 10.1111/bcpt.12090
– ident: e_1_2_9_50_1
  doi: 10.1007/s00213-008-1240-6
– ident: e_1_2_9_35_1
  doi: 10.1586/14737175.2015.1086269
– ident: e_1_2_9_13_1
  doi: 10.2174/1568007024606221
– ident: e_1_2_9_41_1
  doi: 10.1016/j.schres.2016.04.013
– ident: e_1_2_9_57_1
  doi: 10.1517/13543776.2011.565333
– ident: e_1_2_9_16_1
  doi: 10.1016/0024-3205(88)90493-6
– ident: e_1_2_9_24_1
  doi: 10.1177/0269881117728428
– ident: e_1_2_9_5_1
  doi: 10.1021/jm940608g
– ident: e_1_2_9_49_1
  doi: 10.1016/j.pbb.2014.06.008
– ident: e_1_2_9_6_1
  doi: 10.4088/JCP.v62n1201
– ident: e_1_2_9_7_1
  doi: 10.4088/JCP.v63n0903
– ident: e_1_2_9_9_1
  doi: 10.4088/JCP.11m07530
– ident: e_1_2_9_23_1
  doi: 10.1097/JCP.0b013e31828ea95c
– volume: 26
  start-page: 373
  issue: 3
  year: 1990
  ident: e_1_2_9_30_1
  article-title: Treatment of neuroleptic induced akathisia with the 5‐HT2 antagonist ritanserin
  publication-title: Psychopharmacol Bull
– ident: e_1_2_9_12_1
  doi: 10.1124/jpet.114.213819
– volume: 24
  start-page: 371
  issue: 2
  year: 1972
  ident: e_1_2_9_15_1
  article-title: Regulation of monoamine metabolism in the central nervous system
  publication-title: Pharmacol Rev
– ident: e_1_2_9_26_1
  doi: 10.1016/S0920-9964(03)00050-1
– volume: 277
  start-page: 137
  issue: 1
  year: 1996
  ident: e_1_2_9_38_1
  article-title: Effects of the novel antipsychotic agent 7‐{4‐[4‐(2,3‐dichlorophenyl)‐1‐piperazinyl]butyloxy}‐3,4‐dihydro‐2(1H)‐quinolinone (OPC‐14597) on prolactin release from the rat anterior pituitary gland
  publication-title: J Pharmacol Exp Ther
SSID ssj0002000234
Score 2.318376
SecondaryResourceType review_article
Snippet Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D 2 receptor partial agonist approved for schizophrenia, the antipsychotic...
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole...
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 134
SubjectTerms Agonists
Antipsychotics
Aripiprazole - therapeutic use
Depressive Disorder, Major - drug therapy
Dopamine
Dopamine Agonists - therapeutic use
Drug dosages
Humans
Hypotheses
Psychotropic drugs
Quinolones
R&D
Research & development
Schizophrenia
Serotonin
Thiophenes
United States
Title Discovery research and development history of the dopamine D 2 receptor partial agonists, aripiprazole and brexpiprazole
URI https://www.ncbi.nlm.nih.gov/pubmed/33960741
https://www.proquest.com/docview/2535774585
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwEA46X3wRfzudI6AMBMvaNFnbJ3FuQwRlyIS9lUub6kDbuk5w_vVe2q71QX0qtElbeknu-66X7wg5BxNcT4AyQiVNgyvRM1zgwjAjV3AuQYDQu5HvH3q3T_xuKqZlwC0r0ypXa2K-UIdJoGPkXSZsgVAF0e1V-m7oqlH672pZQmOdbGjpMp3S5UydKsbCcjkXXqmSsm6czpkWVNAqkD_90B_gMncyo22yVaJDel2Yc4esqXiXdMaFvPTykk7q3VLZJe3QcS08vdwjn4NZFuiUzCUtNXxeKMQhDevEIFroCy9pElGEfjREzvyGQJMOKMNOOsclmdNUjyd8D3hOtLAuPgoZdTpL5_CVvKr8nsikP6sz--RpNJzc3BplZQUjQFe1MELXDACQSoTo3XsRzmmkXZalAPEi8zjwSHLBFTiADdxAWoGIXFt5SnihvmIfkEacxOqIUCak8kxgjkSu6PYkBGB5jgBLctu2pWqSi9V39oNSdlxXv3j1C8Fk5mub-LlNmuSsapsWYhu_tmqtzOWXEy7z6-HRJIeFCatb2DbSNEROx_93PCGbTCes5CGWFmks5h_qFBHHQrbzYdUmG9f9QX-Ex_7wYfzYzvn7NwB13Qw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9tAEB7RcGgvCOgr5dGV2iJVwsLeR2Ifqqo0oFAgiqogcXNn7TUgge0mqYr7o_iNzPoVDm1vXO3dtbUz3v2-8ew3AO_RRT9QaJzYaNeRRvUcH6Vy3MRXUmpUqOxp5NNRb3gmv52r8yW4a87C2LTKZk0sF-o4i2yMfI8roQiqELr9nP90bNUo-3e1KaFRucWxKX4TZZt9OhqQfT9wfngw-Tp06qoCTkTL9NyJfTdCJBgd087WS8ifiXJ4nkHCSjyQKBMtlTTYR2rgR9qLVOILExgVxPaOoHGfwLIURGU6sLx_MBp_b6M6vBSQka0OKt9L8ym3Eg5Wd_LhzvcPOFtua4ersFLjUfalcqA1WDLpOuyMK0HrYpdNFuezZrtsh40XUtfFc7gdXM0imwRasFo16JJhGrN4kYrEKkXjgmUJI7DJYmLpNwRt2YBx6mSzarIpy60H03vgRWalfOlRxOHzq3yKf7JrU45J3P22vfICzh5l1l9CJ81S8xoYV9oELvK-Jnbq9zRG6AV9hZ6WQghtuvCxmecwqoXObb2N67CSaOahtUlY2qQL79q2eSXv8ddWm425wvoTn4ULh-zCq8qE7RBCEDEkrPbm_x3fwtPh5PQkPDkaHW_AM27TZcoAzyZ05tNfZovwzlxv107G4Mdj-_U9BZgW1w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB5RkKpeqkJfS3lYKkWqRLSJH5vkgBBiWUGhaA8g7S0dJ06LBEm6u1VJfxq_jnFe20PpjWtiO5Hns_2NPf4GYAddDEKFxkmMdh1p1MAJUCrHTQMlpUaFyt5G_noxOLmSXyZqsgT37V0YG1bZzonVRJ3ksd0j73MlFFEVYrf9tAmLGA9HB8VPx2aQsietbTqNGiJnpvxN7tts_3RItv7E-ej48ujEaTIMODFN2XMnCdwYkSh1QqvcICVsk_vheQaJN_FQoky1VNKgj1QgiLUXqzQQJjQqTOwbQe0-gxVfKM-OMX_id_s7vJKSkZ0iKu9nxZRbMQerQPn3GvgIsa0WuNEreNkwU3ZYQ2kVlky2BrvjWtq63GOXi5tasz22y8YL0evyNdwNr2exDQctWaMf9INhlrBkEZTEam3jkuUpI9rJEvLXb4nksiHjVMnG1-RTVlgs03_g99yK-tKnyJsvrosp_slvTNUmefF33ZM3cPUkff4WlrM8M--BcaVN6CL3NfmpwUBjjF7oK_S0FEJo04PPbT9HcSN5bjNv3ES1WDOPrE2iyiY9-NiVLWqhj3-W2mjNFTWDfRYtoNmDd7UJuyaEIBeRWNv6_ytuw3NCc3R-enH2AV5wGzdT7fRswPJ8-stsEvGZ660KYQy-PTWkHwDVlhmn
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discovery+research+and+development+history+of+the+dopamine+D+2+receptor+partial+agonists%2C+aripiprazole+and+brexpiprazole&rft.jtitle=Neuropsychopharmacology+reports&rft.au=Kikuchi%2C+Tetsuro&rft.au=Maeda%2C+Kenji&rft.au=Suzuki%2C+Mikio&rft.au=Hirose%2C+Tsuyoshi&rft.date=2021-06-01&rft.eissn=2574-173X&rft.volume=41&rft.issue=2&rft.spage=134&rft_id=info:doi/10.1002%2Fnpr2.12180&rft_id=info%3Apmid%2F33960741&rft.externalDocID=33960741
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2574-173X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2574-173X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2574-173X&client=summon